General

Home > News > General

The R&D layout of foreign companies in China is not just about the market

2022-07-11

From Made in China to R&D in China, more and more foreign-funded enterprises have adjusted their strategic focus in China and put their core R&D links in China. Foreign R&D centers have gradually become an important part of China's R&D system.

"China's economy is recovering steadily, and it has increasingly become a 'safe haven' for companies to cope with the impact of the epidemic. Increasing investment in R&D in China will help foreign companies to better deepen their business in China." "China has the world's largest consumer market, and the establishment of R&D centers can not only help Promoting the formation of new business models will also promote technological innovation.” “The establishment of R&D centers in China will help foreign companies to timely capture and meet the needs of China’s rapidly developing market and gain greater competitive advantages.” When setting up R&D centers, many foreign companies will talk about this point of view.

Looking at the fields involved in foreign R&D centers, it is not difficult to find popular industries such as biomedicine, information technology, auto parts and chemicals, electronic equipment and machinery manufacturing, which also happen to be the blue ocean of the Chinese consumer market.

What foreign R&D centers smell is only the "smell of money" in the Chinese market? actually not. In the "14th Five-Year Plan" for the development of foreign capital utilization, China clearly will support the R&D centers of foreign-invested enterprises to participate in the national science and technology plan projects, and promote the gathering of high-end factor resources around the world. This undoubtedly cultivates fertile ground for the establishment of foreign R&D centers.

In addition to the central government's announcement of support policies, various localities have also shown their sincerity to attract foreign investment to set up high-tech R&D centers. As of the end of May, the number of Shanghai R&D centers has reached 512.

Of course, foreign investment is not only interested in the market and policy environment, but also in the process of attracting R&D centers, China's innovation capability is also an important consideration.

He Jing, global senior vice president of AstraZeneca and president of the Global R&D China Center, also confirms this point of view: "The reform of China's drug regulatory system has injected great vitality into the biological R&D industry. The supply of high-quality talents, coupled with the return of overseas talents, has formed an abundant talent pool. Since the establishment of the China New Drug R&D Department in 2013, AstraZeneca's R&D in China has gradually upgraded from a 'skillful hand' to a 'brain leading global R&D' 'Think tank. It is estimated that by 2023, AstraZeneca's R&D investment in China will be 2.5 times that of 2020; the number of R&D personnel in China will increase to more than 800, and the personnel growth rate will reach 60% compared with 2020."

In 2021, AstraZeneca will build the first bioanalytical laboratory for innovative biological therapy operated by a multinational pharmaceutical company in Shanghai in Shanghai, supporting the simultaneous advancement of targeted biological drug R&D projects in China and around the world. A few days ago, the company also announced that it will introduce the CoSolve innovation plan project to China for the first time. The project focuses on the "nine innovation needs" in key areas of research and development, solicits solutions from Chinese innovative enterprises and scientific research institutes, and recruits more Chinese innovative forces to participate in global new drugs. R&D.

According to the "2021 Global Innovation Index" released by the World Intellectual Property Organization last year, China's global ranking in the field of innovation has risen from 14th last year to 12th this year. An ecosystem for protecting innovation is taking shape.

With the rise of China's innovative power on a global scale, China's position in the global R&D network of many foreign companies will become more and more important!


DISCLAIMER: All information provided by HMEonline is for reference only. None of these views represents the position of HMEonline, and HMEonline makes no guarantee or commitment to it. If you find any works that infringe your intellectual property rights in the article, please contact us and we will modify or delete them in time.
© 2022 Company, Inc. All rights reserved.
WhatsApp